MAP2K7 and melanoma: The median PFS was 4.4 months, the median OS from the start of BRAFi/MEKi treatment was 18.0 months, and 39% were alive at 3 years, suggesting that BRAF/MEK inhibition is effective in patients with BRAF V600-mutant melanoma previously treated with immunotherapy with response rates similar to those seen in trials of first-line treatment with BRAF/MEK inhibition.